NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).

Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.